NCT02242656
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
Phase: Phase 3
Role: Lead Sponsor
Start: Dec 31, 2014
Completion: Not specified